Please login to the form below

Not currently logged in
Email:
Password:

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

Sanofi

French pharmaceutical company Sanofi has invested €170m to expand its existing vaccine production operations in northern France.

The new Val de Reuil facility will allow Sanofi Pasteur to increase supply of its new quadrivalent influenza vaccine VaxigripTetra.

Philippe Luscan, executive vice president, global industrial affairs, Sanofi, said: “Our investment underlines Sanofi’s intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”

Sanofi - who has made several investments to improve and expand its vaccine production capabilities - plans to complete the expansion by 2021, and will begin producing vaccines in the new facility in 2022.

David Loew, executive vice president, Sanofi, said: “Influenza continues to be a major public health problem around the world, causing serious complications, hospitalisations and deaths, mostly for certain high-risk individuals.

“As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur’s ability to tackle this underestimated health challenge.”

Article by
Gemma Jones

17th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Top Pharma News

TopPharmaNews.com is a global pharma magazine dedicated to delivering fresh news to society. The team at the TopPharmaNews.com cater non-biased,...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics